Medpace Holdings, Inc. (NASDAQ:MEDP) – Investment analysts at Jefferies Group increased their FY2017 earnings per share (EPS) estimates for Medpace Holdings in a research note issued on Tuesday. Jefferies Group analyst D. Windley now expects that the company will post earnings of $1.50 per share for the year, up from their previous forecast of $1.44. Jefferies Group has a “Hold” rating and a $38.00 price target on the stock. Jefferies Group also issued estimates for Medpace Holdings’ Q4 2017 earnings at $0.38 EPS, Q1 2018 earnings at $0.41 EPS, Q3 2018 earnings at $0.44 EPS, Q4 2018 earnings at $0.44 EPS, FY2018 earnings at $1.72 EPS and FY2019 earnings at $1.98 EPS.
A number of other brokerages have also weighed in on MEDP. William Blair lowered Medpace Holdings from an “outperform” rating to a “market perform” rating in a research note on Wednesday. They noted that the move was a valuation call. Robert W. Baird raised their price objective on Medpace Holdings from $32.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday. Zacks Investment Research lowered Medpace Holdings from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. KeyCorp restated a “hold” rating on shares of Medpace Holdings in a research note on Tuesday, October 17th. Finally, Raymond James Financial, Inc. assumed coverage on Medpace Holdings in a research note on Friday, September 29th. They set a “market perform” rating for the company. Seven analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Medpace Holdings currently has an average rating of “Hold” and a consensus price target of $36.60.
TRADEMARK VIOLATION WARNING: “FY2017 EPS Estimates for Medpace Holdings, Inc. (MEDP) Lifted by Jefferies Group” was posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/11/03/fy2017-eps-estimates-for-medpace-holdings-inc-medp-lifted-by-jefferies-group.html. Medpace Holdings (NASDAQ:MEDP) last posted its earnings results on Monday, October 30th. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.04. The firm had revenue of $98.68 million during the quarter, compared to analysts’ expectations of $96.84 million. Medpace Holdings had a return on equity of 10.00% and a net margin of 6.44%. The firm’s revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.40 earnings per share.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Schwab Charles Investment Management Inc. grew its stake in Medpace Holdings by 0.5% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 28,074 shares of the company’s stock valued at $815,000 after purchasing an additional 152 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Medpace Holdings by 1.4% during the 2nd quarter. Goldman Sachs Group Inc. now owns 34,690 shares of the company’s stock worth $1,006,000 after buying an additional 482 shares during the last quarter. Tudor Investment Corp ET AL lifted its holdings in Medpace Holdings by 16.4% during the 1st quarter. Tudor Investment Corp ET AL now owns 6,864 shares of the company’s stock worth $205,000 after buying an additional 967 shares during the last quarter. Rhumbline Advisers lifted its holdings in Medpace Holdings by 13.3% during the 2nd quarter. Rhumbline Advisers now owns 9,726 shares of the company’s stock worth $282,000 after buying an additional 1,140 shares during the last quarter. Finally, Teachers Advisors LLC lifted its holdings in Medpace Holdings by 9.1% during the 1st quarter. Teachers Advisors LLC now owns 27,271 shares of the company’s stock worth $814,000 after buying an additional 2,278 shares during the last quarter. Hedge funds and other institutional investors own 16.32% of the company’s stock.
In other Medpace Holdings news, major shareholder Medpace Limited Partnership sold 2,000,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $30.27, for a total transaction of $60,540,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 25.80% of the stock is owned by company insiders.
Medpace Holdings Company Profile
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
What are top analysts saying about Medpace Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Medpace Holdings Inc. and related companies.